Genprex, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GNPX Nasdaq 2836 www.genprex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genprex, Inc.

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Jun 24th, 2025 7:25 am
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions - Jun 23rd, 2025 7:00 am
Genprex to Participate at BIO 2025 International Convention - Jun 3rd, 2025 5:00 am
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - May 29th, 2025 5:00 am
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - May 28th, 2025 5:00 am
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - May 7th, 2025 5:00 am
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - May 6th, 2025 5:00 am
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - Apr 30th, 2025 5:30 am
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - Apr 29th, 2025 5:30 am
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - Apr 28th, 2025 5:30 am
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Apr 24th, 2025 6:15 am
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings - Apr 22nd, 2025 6:15 am
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - Mar 26th, 2025 6:15 am
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Mar 25th, 2025 6:15 am
Genprex to Participate at BIO Europe Spring 2025 - Mar 4th, 2025 6:15 am
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System - Feb 19th, 2025 6:15 am
Genprex Provides Update on Diabetes Gene Therapy Program - Feb 18th, 2025 6:15 am
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - Feb 13th, 2025 6:15 am
Genprex doses first subject in expansion part of lung cancer gene therapy trial - Jan 24th, 2025 5:28 am
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - Jan 23rd, 2025 6:00 am